Feasibility of dose accumulation for assessing treatment-related side effects in MR-guided abdominal SABR: A single-institution study

Le résumé fourni par la source

Background: Daily adaptive magnetic resonance (MR)-guided treatment changes delivered dose distributions, making cumulative dose uncertain. This work assessed the feasibility of exploring potential relationships between side effects and accumulated dose (AD) in MR-guided stereotactic ablative radiotherapy (SABR) for liver and pancreatic cancers. Using deformable image registration (DIR), AD to abdominal organs at risk (OARs) were estimated and potential relationships with observed side effects explored. Methods: Forty-one patients treated with 5-fraction MR-guided SABR to primary or metastatic pancreatic and liver tumours were retrospectively included. Daily adapted plans were deformably mapped and summed to estimate AD. Differences between accumulated and planned dose were assessed. Changes in clinician-reported symptoms collected at baseline, 3, and 6 months were analysed. Associations between AD and symptoms were assessed using Spearman's rank test. Results: < 0.040). All side effects were ≤ grade (G) 2. Median overall survival for locally advanced pancreatic cancer (LAPC) patients was 16.0 months post-SABR and was not reached for other subgroups. Conclusion: Exploring potential relationships between DIR-based accumulated OAR dose and side effects was feasible. Preliminary relationships between accumulated OAR dose and side effects were observed; however, further work in larger studies is warranted before these findings can be used to personalise treatment in the future.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.